Contrast-Enhanced Mammography for Women with Palpable Breast Abnormalities

Abstract

To examine the role of contrast-enhanced mammography (CEM) in the work-up of palpable breast abnormalities. In this single-center combination prospective-retrospective study, women with palpable breast abnormalities underwent CEM evaluation prospectively, comprising the acquisition of low energy (LE) images and recombined images (RI) which depict enhancement, followed by targeted ultrasound (US). Two independent readers retrospectively reviewed the imaging and assigned BI-RADS assessment based on LE alone, LE plus US, RI with LE plus US (CEM plus US), and RI alone. Pathology results or 1-year follow-up imaging served as the reference standard. 237 women with 262 palpable abnormalities were included (mean age, 51 years). Of the 262 palpable abnormalities, 116/262 (44%) had no imaging correlate and 242/262 (92%) were benign. RI alone had better specificity compared toLE plus US (Reader 1, 94% versus 89% (p=0.009); Reader 2, 93% versus 88% (p=0.03)), better positive predictive value (Reader 1, 52% versus 42% (p=0.04); Reader 2, 53% versus 42% (p=0.04)), and better accuracy (Reader 1, 93% versus 89% (p=0.05); Reader 2, 93% versus 90% (p=0.06)). CEM plus US was not significantly different in performance metrics versus LE plus US. RI had better specificity compared toLE in combination with US. There was no difference in performance between CEM plus US and LE plus US, likely reflecting the weight US carries in radiologist decision-making. However, the results indicate that the absence of enhancement on RI in the setting of palpable lesions may help avoid benign biopsies.